148 related articles for article (PubMed ID: 15730388)
1. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma.
Matsushita M; Yamamoto T; Nishioka K
Clin Exp Immunol; 2005 Mar; 139(3):429-38. PubMed ID: 15730388
[TBL] [Abstract][Full Text] [Related]
2. Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
Clin Immunol; 2002 Jan; 102(1):77-83. PubMed ID: 11781070
[TBL] [Abstract][Full Text] [Related]
3. Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
J Invest Dermatol; 2003 Sep; 121(3):510-6. PubMed ID: 12925209
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-'susceptible' mouse strains.
Oi M; Yamamoto T; Nishioka K
J Med Dent Sci; 2004 Mar; 51(1):7-17. PubMed ID: 15137460
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.
Matsushita M; Yamamoto T; Nishioka K
Int Arch Allergy Immunol; 2004 Dec; 135(4):348-56. PubMed ID: 15564778
[TBL] [Abstract][Full Text] [Related]
6. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
[TBL] [Abstract][Full Text] [Related]
7. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
J Invest Dermatol; 2004 Jan; 122(1):44-50. PubMed ID: 14962088
[TBL] [Abstract][Full Text] [Related]
8. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts.
Murota H; Hamasaki Y; Nakashima T; Yamamoto K; Katayama I; Matsuyama T
Arthritis Rheum; 2003 Apr; 48(4):1117-25. PubMed ID: 12687556
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma.
Wu MH; Yokozeki H; Takagawa S; Yamamoto T; Satoh T; Kaneda Y; Katayama I; Nishioka K
Gene Ther; 2004 Jan; 11(2):170-80. PubMed ID: 14712301
[TBL] [Abstract][Full Text] [Related]
10. UVA irradiation following treatment with topical 8-methoxypsoralen improves bleomycin-induced scleroderma in a mouse model, by reducing the collagen content and collagen gene expression levels in the skin.
Hayashi S; Ikeda M; Kitamura Y; Hamasaki Y; Hatamochi A
J Dermatol Sci; 2012 Jul; 67(1):20-5. PubMed ID: 22486844
[TBL] [Abstract][Full Text] [Related]
11. Investigation of sensory neurogenic components in a bleomycin-induced scleroderma model using transient receptor potential vanilloid 1 receptor- and calcitonin gene-related peptide-knockout mice.
Szabó A; Czirják L; Sándor Z; Helyes Z; László T; Elekes K; Czömpöly T; Starr A; Brain S; Szolcsányi J; Pintér E
Arthritis Rheum; 2008 Jan; 58(1):292-301. PubMed ID: 18163477
[TBL] [Abstract][Full Text] [Related]
12. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.
Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K
J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374
[TBL] [Abstract][Full Text] [Related]
13. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma.
Yamamoto T; Yokozeki H; Nishioka K
Arch Dermatol Res; 2007 Feb; 298(9):465-8. PubMed ID: 17102953
[TBL] [Abstract][Full Text] [Related]
14. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains.
Yamamoto T; Kuroda M; Nishioka K
Arch Dermatol Res; 2000 Nov; 292(11):535-41. PubMed ID: 11194891
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma.
Kohno S; Endo H; Hashimoto A; Hayashi I; Murakami Y; Kitasato H; Kojima F; Kawai S; Kondo H
Biomed Pharmacother; 2006 Jan; 60(1):18-25. PubMed ID: 16337105
[TBL] [Abstract][Full Text] [Related]
16. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma.
Yamamoto T; Takagawa S; Katayama I; Nishioka K
Clin Immunol; 1999 Jul; 92(1):6-13. PubMed ID: 10413648
[TBL] [Abstract][Full Text] [Related]
17. Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma.
Nakamura-Wakatsuki T; Oyama N; Yamamoto T
Exp Dermatol; 2012 Mar; 21(3):189-94. PubMed ID: 22188586
[TBL] [Abstract][Full Text] [Related]
18. Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1.
Lemaire R; Burwell T; Sun H; Delaney T; Bakken J; Cheng L; Rebelatto MC; Czapiga M; de-Mendez I; Coyle AJ; Herbst R; Lafyatis R; Connor J
Arthritis Rheumatol; 2016 Feb; 68(2):473-83. PubMed ID: 26414805
[TBL] [Abstract][Full Text] [Related]
19. Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model.
Stegemann A; Sindrilaru A; Eckes B; del Rey A; Heinick A; Schulte JS; Müller FU; Grando SA; Fiebich BL; Scharffetter-Kochanek K; Luger TA; Böhm M
Arthritis Rheum; 2013 Mar; 65(3):792-804. PubMed ID: 23440693
[TBL] [Abstract][Full Text] [Related]
20. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
Kapoor M; McCann M; Liu S; Huh K; Denton CP; Abraham DJ; Leask A
Arthritis Rheum; 2009 Sep; 60(9):2822-9. PubMed ID: 19714649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
